LOSARTAN POTASSIUM
All strengths: General benefit; same patient cost rules
Shared coverage and patient cost rules
StatusGeneral benefit
Patient paysPatient pays: program not supplied; amount cannot be determined.
Other products in the same Health Canada class (C09CA) — coverage varies; not interchangeable
- Candesartan cilexetil (Atacand): general benefit
- Irbesartan (Avapro): general benefit, Not a benefit
- Olmesartan medoxomil (Olmetec): general benefit
- Telmisartan (Micardis): general benefit
- Valsartan (Diovan): general benefit, Not a benefit
- Eprosartan (Teveten): general benefit
Auro-Losartan · DIN 02403323 · 25mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Auro-Losartan · DIN 02403323
Manufacturer: Auro Pharma Inc.; listing date 2013-05-31
Health Canada: Marketed since 2013-03-26 · brand AURO-LOSARTAN · ATC C09CA01 LOSARTAN · form Tablet · route Oral · ingredients LOSARTAN POTASSIUM 25.0 MG · company Auro pharma inc · schedule Prescription
Auro-Losartan: Formulary list price $0.3147/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.3147 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88814 · Verify on the e-Formulary ↗ (DIN 02403323)
Source record
DIN 02403323: Auro-Losartan
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800212; group id 335; item number 0757; lccId None; manufacturer id AUR
Source form: Tab; strength: 25mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.3147; ministry $0.3147
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02403323
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88814
Interchangeable products
Apo-Losartan · DIN 02379058 · $0.3147
Bio-Losartan · DIN 02445964 · $0.3147
Co Losartan · DIN 02354829 · $0.3147
Cozaar · DIN 02182815 · $0.3147
Jamp-Losartan · DIN 02398834 · $0.3147
Losartan · DIN 02388790 · $0.3147
Losartan · DIN 02388863 · $0.3147
Mint-Losartan · DIN 02405733 · $0.3147
PMS-Losartan · DIN 02309750 · $0.3147
Ran-Losartan · DIN 02404451 · $0.3147
Sandoz Losartan · DIN 02313332 · $0.3147
Septa-Losartan · DIN 02424967 · $0.3147
Teva-Losartan · DIN 02380838 · $0.3147
Shortage status: resolved shortage (ended 2023-12-06); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02403323
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Cozaar · DIN 02182815 · 25mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Cozaar · DIN 02182815
Manufacturer: Organon Canada Inc.; listing date 1996-10-01
Health Canada: Marketed since 2022-02-21 · brand COZAAR · ATC C09CA01 LOSARTAN · form Tablet · route Oral · ingredients LOSARTAN POTASSIUM 25 MG · company Organon canada inc. · schedule Prescription
Ministry pays: $0.3147 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19167 · Verify on the e-Formulary ↗ (DIN 02182815)
Source record
DIN 02182815: Cozaar
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800212; group id 335; item number 0757; lccId None; manufacturer id OCI
Source form: Tab; strength: 25mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $1.9924; ministry $0.3147
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02182815
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19167
Interchangeable products
Apo-Losartan · DIN 02379058 · $0.3147
Auro-Losartan · DIN 02403323 · $0.3147
Bio-Losartan · DIN 02445964 · $0.3147
Co Losartan · DIN 02354829 · $0.3147
Jamp-Losartan · DIN 02398834 · $0.3147
Losartan · DIN 02388790 · $0.3147
Losartan · DIN 02388863 · $0.3147
Mint-Losartan · DIN 02405733 · $0.3147
PMS-Losartan · DIN 02309750 · $0.3147
Ran-Losartan · DIN 02404451 · $0.3147
Sandoz Losartan · DIN 02313332 · $0.3147
Septa-Losartan · DIN 02424967 · $0.3147
Teva-Losartan · DIN 02380838 · $0.3147
Shortage status: avoided shortage; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02182815
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Jamp-Losartan · DIN 02398834 · 25mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Jamp-Losartan · DIN 02398834
Manufacturer: Jamp Pharma Corporation; listing date 2013-05-31
Health Canada: Marketed since 2016-06-01 · brand JAMP-LOSARTAN · ATC C09CA01 LOSARTAN · form Tablet · route Oral · ingredients LOSARTAN POTASSIUM 25 MG · company Jamp pharma corporation · schedule Prescription
Jamp-Losartan: Formulary list price $0.3147/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.3147 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88375 · Verify on the e-Formulary ↗ (DIN 02398834)
Source record
DIN 02398834: Jamp-Losartan
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800212; group id 335; item number 0757; lccId None; manufacturer id JPC
Source form: Tab; strength: 25mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.3147; ministry $0.3147
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02398834
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88375
Interchangeable products
Apo-Losartan · DIN 02379058 · $0.3147
Auro-Losartan · DIN 02403323 · $0.3147
Bio-Losartan · DIN 02445964 · $0.3147
Co Losartan · DIN 02354829 · $0.3147
Cozaar · DIN 02182815 · $0.3147
Losartan · DIN 02388790 · $0.3147
Losartan · DIN 02388863 · $0.3147
Mint-Losartan · DIN 02405733 · $0.3147
PMS-Losartan · DIN 02309750 · $0.3147
Ran-Losartan · DIN 02404451 · $0.3147
Sandoz Losartan · DIN 02313332 · $0.3147
Septa-Losartan · DIN 02424967 · $0.3147
Teva-Losartan · DIN 02380838 · $0.3147
Shortage status: active shortage (reported 2024-12-23, estimated to end 2026-12-31, last updated 2026-04-22); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02398834
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Losartan · DIN 02388790 · 25mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Losartan · DIN 02388790
Manufacturer: Sivem Pharmaceuticals ULC; listing date 2020-06-30
Health Canada: Marketed since 2025-06-12 · brand LOSARTAN · ATC C09CA01 LOSARTAN · form Tablet · route Oral · ingredients LOSARTAN POTASSIUM 25 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Losartan: Formulary list price $0.3147/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.3147 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87431 · Verify on the e-Formulary ↗ (DIN 02388790)
Source record
DIN 02388790: Losartan
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800212; group id 335; item number 0757; lccId None; manufacturer id SIV
Source form: Tab; strength: 25mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.3147; ministry $0.3147
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02388790
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87431
Interchangeable products
Apo-Losartan · DIN 02379058 · $0.3147
Auro-Losartan · DIN 02403323 · $0.3147
Bio-Losartan · DIN 02445964 · $0.3147
Co Losartan · DIN 02354829 · $0.3147
Cozaar · DIN 02182815 · $0.3147
Jamp-Losartan · DIN 02398834 · $0.3147
Losartan · DIN 02388863 · $0.3147
Mint-Losartan · DIN 02405733 · $0.3147
PMS-Losartan · DIN 02309750 · $0.3147
Ran-Losartan · DIN 02404451 · $0.3147
Sandoz Losartan · DIN 02313332 · $0.3147
Septa-Losartan · DIN 02424967 · $0.3147
Teva-Losartan · DIN 02380838 · $0.3147
Shortage status: active shortage (reported 2021-05-26, last updated 2021-05-27) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02388790
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Losartan · DIN 02388863 · 25mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Losartan · DIN 02388863
Manufacturer: Sanis Health Inc.; listing date 2021-01-29
Health Canada: Marketed since 2012-07-20 · brand LOSARTAN · ATC C09CA01 LOSARTAN · form Tablet · route Oral · ingredients LOSARTAN POTASSIUM 25 MG · company Sanis health inc · schedule Prescription
Losartan: Formulary list price $0.3147/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.3147 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87441 · Verify on the e-Formulary ↗ (DIN 02388863)
Source record
DIN 02388863: Losartan
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800212; group id 335; item number 0757; lccId None; manufacturer id SAI
Source form: Tab; strength: 25mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.3147; ministry $0.3147
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02388863
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87441
Interchangeable products
Apo-Losartan · DIN 02379058 · $0.3147
Auro-Losartan · DIN 02403323 · $0.3147
Bio-Losartan · DIN 02445964 · $0.3147
Co Losartan · DIN 02354829 · $0.3147
Cozaar · DIN 02182815 · $0.3147
Jamp-Losartan · DIN 02398834 · $0.3147
Losartan · DIN 02388790 · $0.3147
Mint-Losartan · DIN 02405733 · $0.3147
PMS-Losartan · DIN 02309750 · $0.3147
Ran-Losartan · DIN 02404451 · $0.3147
Sandoz Losartan · DIN 02313332 · $0.3147
Septa-Losartan · DIN 02424967 · $0.3147
Teva-Losartan · DIN 02380838 · $0.3147
Shortage status: resolved shortage (ended 2024-12-02); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02388863
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Mint-Losartan · DIN 02405733 · 25mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Mint-Losartan · DIN 02405733
Manufacturer: Mint Pharmaceuticals Inc.; listing date 2014-05-29
Health Canada: Marketed since 2024-03-22 · brand MINT-LOSARTAN · ATC C09CA01 LOSARTAN · form Tablet · route Oral · ingredients LOSARTAN POTASSIUM 25 MG · company Mint pharmaceuticals inc · schedule Prescription
Mint-Losartan: Formulary list price $0.3147/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.3147 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89050 · Verify on the e-Formulary ↗ (DIN 02405733)
Source record
DIN 02405733: Mint-Losartan
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800212; group id 335; item number 0757; lccId None; manufacturer id MIN
Source form: Tab; strength: 25mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.3147; ministry $0.3147
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02405733
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89050
Interchangeable products
Apo-Losartan · DIN 02379058 · $0.3147
Auro-Losartan · DIN 02403323 · $0.3147
Bio-Losartan · DIN 02445964 · $0.3147
Co Losartan · DIN 02354829 · $0.3147
Cozaar · DIN 02182815 · $0.3147
Jamp-Losartan · DIN 02398834 · $0.3147
Losartan · DIN 02388790 · $0.3147
Losartan · DIN 02388863 · $0.3147
PMS-Losartan · DIN 02309750 · $0.3147
Ran-Losartan · DIN 02404451 · $0.3147
Sandoz Losartan · DIN 02313332 · $0.3147
Septa-Losartan · DIN 02424967 · $0.3147
Teva-Losartan · DIN 02380838 · $0.3147
Shortage status: resolved shortage (ended 2024-03-22); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02405733
Shortage record checked 2026-09-13T08:10:21.292534+00:00
PMS-Losartan · DIN 02309750 · 25mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
PMS-Losartan · DIN 02309750
Manufacturer: Pharmascience Inc.; listing date 2012-03-26
Health Canada: Marketed since 2020-12-16 · brand PMS-LOSARTAN · ATC C09CA01 LOSARTAN · form Tablet · route Oral · ingredients LOSARTAN POTASSIUM 25 MG · company Pharmascience inc · schedule Prescription
PMS-Losartan: Formulary list price $0.3147/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.3147 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=79542 · Verify on the e-Formulary ↗ (DIN 02309750)
Source record
DIN 02309750: PMS-Losartan
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800212; group id 335; item number 0757; lccId None; manufacturer id PMS
Source form: Tab; strength: 25mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.3147; ministry $0.3147
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02309750
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=79542
Interchangeable products
Apo-Losartan · DIN 02379058 · $0.3147
Auro-Losartan · DIN 02403323 · $0.3147
Bio-Losartan · DIN 02445964 · $0.3147
Co Losartan · DIN 02354829 · $0.3147
Cozaar · DIN 02182815 · $0.3147
Jamp-Losartan · DIN 02398834 · $0.3147
Losartan · DIN 02388790 · $0.3147
Losartan · DIN 02388863 · $0.3147
Mint-Losartan · DIN 02405733 · $0.3147
Ran-Losartan · DIN 02404451 · $0.3147
Sandoz Losartan · DIN 02313332 · $0.3147
Septa-Losartan · DIN 02424967 · $0.3147
Teva-Losartan · DIN 02380838 · $0.3147
Shortage status: resolved shortage (ended 2024-07-09); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02309750
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Sandoz Losartan · DIN 02313332 · 25mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Sandoz Losartan · DIN 02313332
Manufacturer: Sandoz Canada Inc.; listing date 2012-03-26
Health Canada: Marketed since 2012-01-25 · brand SANDOZ LOSARTAN · ATC C09CA01 LOSARTAN · form Tablet · route Oral · ingredients LOSARTAN POTASSIUM 25 MG · company Sandoz canada incorporated · schedule Prescription
Sandoz Losartan: Formulary list price $0.3147/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.3147 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=79886 · Verify on the e-Formulary ↗ (DIN 02313332)
Source record
DIN 02313332: Sandoz Losartan
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800212; group id 335; item number 0757; lccId None; manufacturer id SDZ
Source form: Tab; strength: 25mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.3147; ministry $0.3147
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02313332
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=79886
Interchangeable products
Apo-Losartan · DIN 02379058 · $0.3147
Auro-Losartan · DIN 02403323 · $0.3147
Bio-Losartan · DIN 02445964 · $0.3147
Co Losartan · DIN 02354829 · $0.3147
Cozaar · DIN 02182815 · $0.3147
Jamp-Losartan · DIN 02398834 · $0.3147
Losartan · DIN 02388790 · $0.3147
Losartan · DIN 02388863 · $0.3147
Mint-Losartan · DIN 02405733 · $0.3147
PMS-Losartan · DIN 02309750 · $0.3147
Ran-Losartan · DIN 02404451 · $0.3147
Septa-Losartan · DIN 02424967 · $0.3147
Teva-Losartan · DIN 02380838 · $0.3147
Shortage status: resolved shortage (ended 2026-07-06); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02313332
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Teva-Losartan · DIN 02380838 · 25mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Teva-Losartan · DIN 02380838
Manufacturer: Teva Canada Limited; listing date 2012-04-24
Health Canada: Marketed since 2012-02-28 · brand TEVA-LOSARTAN · ATC C09CA01 LOSARTAN · form Tablet · route Oral · ingredients LOSARTAN POTASSIUM 25 MG · company Teva canada limited · schedule Prescription
Ministry pays: $0.3147 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86659 · Verify on the e-Formulary ↗ (DIN 02380838)
Source record
DIN 02380838: Teva-Losartan
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800212; group id 335; item number 0757; lccId None; manufacturer id TEV
Source form: Tab; strength: 25mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.3148; ministry $0.3147
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02380838
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86659
Interchangeable products
Apo-Losartan · DIN 02379058 · $0.3147
Auro-Losartan · DIN 02403323 · $0.3147
Bio-Losartan · DIN 02445964 · $0.3147
Co Losartan · DIN 02354829 · $0.3147
Cozaar · DIN 02182815 · $0.3147
Jamp-Losartan · DIN 02398834 · $0.3147
Losartan · DIN 02388790 · $0.3147
Losartan · DIN 02388863 · $0.3147
Mint-Losartan · DIN 02405733 · $0.3147
PMS-Losartan · DIN 02309750 · $0.3147
Ran-Losartan · DIN 02404451 · $0.3147
Sandoz Losartan · DIN 02313332 · $0.3147
Septa-Losartan · DIN 02424967 · $0.3147
Shortage status: resolved shortage (ended 2024-03-28); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02380838
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Auro-Losartan · DIN 02403331 · 50mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Auro-Losartan · DIN 02403331
Manufacturer: Auro Pharma Inc.; listing date 2013-05-31
Health Canada: Marketed since 2013-03-26 · brand AURO-LOSARTAN · ATC C09CA01 LOSARTAN · form Tablet · route Oral · ingredients LOSARTAN POTASSIUM 50.0 MG · company Auro pharma inc · schedule Prescription
Auro-Losartan: Formulary list price $0.3147/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.3147 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88815 · Verify on the e-Formulary ↗ (DIN 02403331)
Source record
DIN 02403331: Auro-Losartan
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800216; group id 335; item number 0758; lccId None; manufacturer id AUR
Source form: Tab; strength: 50mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.3147; ministry $0.3147
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02403331
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88815
Interchangeable products
Apo-Losartan · DIN 02353504 · $0.3147
Bio-Losartan · DIN 02445972 · $0.3147
Co Losartan · DIN 02354837 · $0.3147
Cozaar · DIN 02182874 · $0.3147
Jamp-Losartan · DIN 02398842 · $0.3147
Losartan · DIN 02388804 · $0.3147
Losartan · DIN 02388871 · $0.3147
Mint-Losartan · DIN 02405741 · $0.3147
PMS-Losartan · DIN 02309769 · $0.3147
Ran-Losartan · DIN 02404478 · $0.3147
Sandoz Losartan · DIN 02313340 · $0.3147
Septa-Losartan · DIN 02424975 · $0.3147
Teva-Losartan · DIN 02357968 · $0.3147
Shortage status: discontinued (2023-11-21, reported by AURO PHARMA INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02403331
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Cozaar · DIN 02182874 · 50mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Cozaar · DIN 02182874
Manufacturer: Organon Canada Inc.; listing date 1996-10-01
Health Canada: Marketed since 2022-01-05 · brand COZAAR · ATC C09CA01 LOSARTAN · form Tablet · route Oral · ingredients LOSARTAN POTASSIUM 50 MG · company Organon canada inc. · schedule Prescription
Ministry pays: $0.3147 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19168 · Verify on the e-Formulary ↗ (DIN 02182874)
Source record
DIN 02182874: Cozaar
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800216; group id 335; item number 0758; lccId None; manufacturer id OCI
Source form: Tab; strength: 50mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $1.9924; ministry $0.3147
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02182874
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19168
Interchangeable products
Apo-Losartan · DIN 02353504 · $0.3147
Auro-Losartan · DIN 02403331 · $0.3147
Bio-Losartan · DIN 02445972 · $0.3147
Co Losartan · DIN 02354837 · $0.3147
Jamp-Losartan · DIN 02398842 · $0.3147
Losartan · DIN 02388804 · $0.3147
Losartan · DIN 02388871 · $0.3147
Mint-Losartan · DIN 02405741 · $0.3147
PMS-Losartan · DIN 02309769 · $0.3147
Ran-Losartan · DIN 02404478 · $0.3147
Sandoz Losartan · DIN 02313340 · $0.3147
Septa-Losartan · DIN 02424975 · $0.3147
Teva-Losartan · DIN 02357968 · $0.3147
Shortage status: resolved shortage (ended 2023-07-28); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02182874
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Jamp-Losartan · DIN 02398842 · 50mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Jamp-Losartan · DIN 02398842
Manufacturer: Jamp Pharma Corporation; listing date 2013-05-31
Health Canada: Marketed since 2016-06-01 · brand JAMP-LOSARTAN · ATC C09CA01 LOSARTAN · form Tablet · route Oral · ingredients LOSARTAN POTASSIUM 50 MG · company Jamp pharma corporation · schedule Prescription
Jamp-Losartan: Formulary list price $0.3147/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.3147 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88376 · Verify on the e-Formulary ↗ (DIN 02398842)
Source record
DIN 02398842: Jamp-Losartan
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800216; group id 335; item number 0758; lccId None; manufacturer id JPC
Source form: Tab; strength: 50mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.3147; ministry $0.3147
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02398842
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88376
Interchangeable products
Apo-Losartan · DIN 02353504 · $0.3147
Auro-Losartan · DIN 02403331 · $0.3147
Bio-Losartan · DIN 02445972 · $0.3147
Co Losartan · DIN 02354837 · $0.3147
Cozaar · DIN 02182874 · $0.3147
Losartan · DIN 02388804 · $0.3147
Losartan · DIN 02388871 · $0.3147
Mint-Losartan · DIN 02405741 · $0.3147
PMS-Losartan · DIN 02309769 · $0.3147
Ran-Losartan · DIN 02404478 · $0.3147
Sandoz Losartan · DIN 02313340 · $0.3147
Septa-Losartan · DIN 02424975 · $0.3147
Teva-Losartan · DIN 02357968 · $0.3147
Shortage status: active shortage (reported 2026-03-12, estimated to end 2026-12-31, last updated 2026-03-28); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02398842
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Losartan · DIN 02388804 · 50mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Losartan · DIN 02388804
Manufacturer: Sivem Pharmaceuticals ULC; listing date 2020-06-30
Health Canada: Marketed since 2025-06-12 · brand LOSARTAN · ATC C09CA01 LOSARTAN · form Tablet · route Oral · ingredients LOSARTAN POTASSIUM 50 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Losartan: Formulary list price $0.3147/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.3147 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87432 · Verify on the e-Formulary ↗ (DIN 02388804)
Source record
DIN 02388804: Losartan
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800216; group id 335; item number 0758; lccId None; manufacturer id SIV
Source form: Tab; strength: 50mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.3147; ministry $0.3147
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02388804
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87432
Interchangeable products
Apo-Losartan · DIN 02353504 · $0.3147
Auro-Losartan · DIN 02403331 · $0.3147
Bio-Losartan · DIN 02445972 · $0.3147
Co Losartan · DIN 02354837 · $0.3147
Cozaar · DIN 02182874 · $0.3147
Jamp-Losartan · DIN 02398842 · $0.3147
Losartan · DIN 02388871 · $0.3147
Mint-Losartan · DIN 02405741 · $0.3147
PMS-Losartan · DIN 02309769 · $0.3147
Ran-Losartan · DIN 02404478 · $0.3147
Sandoz Losartan · DIN 02313340 · $0.3147
Septa-Losartan · DIN 02424975 · $0.3147
Teva-Losartan · DIN 02357968 · $0.3147
Shortage status: active shortage (reported 2021-05-26, last updated 2021-05-27) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02388804
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Losartan · DIN 02388871 · 50mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Losartan · DIN 02388871
Manufacturer: Sanis Health Inc.; listing date 2021-01-29
Health Canada: Marketed since 2012-07-20 · brand LOSARTAN · ATC C09CA01 LOSARTAN · form Tablet · route Oral · ingredients LOSARTAN POTASSIUM 50 MG · company Sanis health inc · schedule Prescription
Losartan: Formulary list price $0.3147/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.3147 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87442 · Verify on the e-Formulary ↗ (DIN 02388871)
Source record
DIN 02388871: Losartan
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800216; group id 335; item number 0758; lccId None; manufacturer id SAI
Source form: Tab; strength: 50mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.3147; ministry $0.3147
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02388871
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87442
Interchangeable products
Apo-Losartan · DIN 02353504 · $0.3147
Auro-Losartan · DIN 02403331 · $0.3147
Bio-Losartan · DIN 02445972 · $0.3147
Co Losartan · DIN 02354837 · $0.3147
Cozaar · DIN 02182874 · $0.3147
Jamp-Losartan · DIN 02398842 · $0.3147
Losartan · DIN 02388804 · $0.3147
Mint-Losartan · DIN 02405741 · $0.3147
PMS-Losartan · DIN 02309769 · $0.3147
Ran-Losartan · DIN 02404478 · $0.3147
Sandoz Losartan · DIN 02313340 · $0.3147
Septa-Losartan · DIN 02424975 · $0.3147
Teva-Losartan · DIN 02357968 · $0.3147
Shortage status: resolved shortage (ended 2026-07-22); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02388871
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Mint-Losartan · DIN 02405741 · 50mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Mint-Losartan · DIN 02405741
Manufacturer: Mint Pharmaceuticals Inc.; listing date 2014-05-29
Health Canada: Marketed since 2024-03-22 · brand MINT-LOSARTAN · ATC C09CA01 LOSARTAN · form Tablet · route Oral · ingredients LOSARTAN POTASSIUM 50 MG · company Mint pharmaceuticals inc · schedule Prescription
Mint-Losartan: Formulary list price $0.3147/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.3147 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89051 · Verify on the e-Formulary ↗ (DIN 02405741)
Source record
DIN 02405741: Mint-Losartan
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800216; group id 335; item number 0758; lccId None; manufacturer id MIN
Source form: Tab; strength: 50mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.3147; ministry $0.3147
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02405741
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89051
Interchangeable products
Apo-Losartan · DIN 02353504 · $0.3147
Auro-Losartan · DIN 02403331 · $0.3147
Bio-Losartan · DIN 02445972 · $0.3147
Co Losartan · DIN 02354837 · $0.3147
Cozaar · DIN 02182874 · $0.3147
Jamp-Losartan · DIN 02398842 · $0.3147
Losartan · DIN 02388804 · $0.3147
Losartan · DIN 02388871 · $0.3147
PMS-Losartan · DIN 02309769 · $0.3147
Ran-Losartan · DIN 02404478 · $0.3147
Sandoz Losartan · DIN 02313340 · $0.3147
Septa-Losartan · DIN 02424975 · $0.3147
Teva-Losartan · DIN 02357968 · $0.3147
Shortage status: resolved shortage (ended 2024-03-22); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02405741
Shortage record checked 2026-09-13T08:10:21.292534+00:00
PMS-Losartan · DIN 02309769 · 50mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
PMS-Losartan · DIN 02309769
Manufacturer: Pharmascience Inc.; listing date 2012-03-26
Health Canada: Marketed since 2020-11-05 · brand PMS-LOSARTAN · ATC C09CA01 LOSARTAN · form Tablet · route Oral · ingredients LOSARTAN POTASSIUM 50 MG · company Pharmascience inc · schedule Prescription
PMS-Losartan: Formulary list price $0.3147/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.3147 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=79543 · Verify on the e-Formulary ↗ (DIN 02309769)
Source record
DIN 02309769: PMS-Losartan
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800216; group id 335; item number 0758; lccId None; manufacturer id PMS
Source form: Tab; strength: 50mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.3147; ministry $0.3147
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02309769
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=79543
Interchangeable products
Apo-Losartan · DIN 02353504 · $0.3147
Auro-Losartan · DIN 02403331 · $0.3147
Bio-Losartan · DIN 02445972 · $0.3147
Co Losartan · DIN 02354837 · $0.3147
Cozaar · DIN 02182874 · $0.3147
Jamp-Losartan · DIN 02398842 · $0.3147
Losartan · DIN 02388804 · $0.3147
Losartan · DIN 02388871 · $0.3147
Mint-Losartan · DIN 02405741 · $0.3147
Ran-Losartan · DIN 02404478 · $0.3147
Sandoz Losartan · DIN 02313340 · $0.3147
Septa-Losartan · DIN 02424975 · $0.3147
Teva-Losartan · DIN 02357968 · $0.3147
Shortage status: active shortage (reported 2026-08-07, estimated to end 2026-09-29, last updated 2026-09-04); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02309769
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Sandoz Losartan · DIN 02313340 · 50mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Sandoz Losartan · DIN 02313340
Manufacturer: Sandoz Canada Inc.; listing date 2012-03-26
Health Canada: Marketed since 2012-01-25 · brand SANDOZ LOSARTAN · ATC C09CA01 LOSARTAN · form Tablet · route Oral · ingredients LOSARTAN POTASSIUM 50 MG · company Sandoz canada incorporated · schedule Prescription
Sandoz Losartan: Formulary list price $0.3147/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.3147 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=79887 · Verify on the e-Formulary ↗ (DIN 02313340)
Source record
DIN 02313340: Sandoz Losartan
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800216; group id 335; item number 0758; lccId None; manufacturer id SDZ
Source form: Tab; strength: 50mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.3147; ministry $0.3147
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02313340
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=79887
Interchangeable products
Apo-Losartan · DIN 02353504 · $0.3147
Auro-Losartan · DIN 02403331 · $0.3147
Bio-Losartan · DIN 02445972 · $0.3147
Co Losartan · DIN 02354837 · $0.3147
Cozaar · DIN 02182874 · $0.3147
Jamp-Losartan · DIN 02398842 · $0.3147
Losartan · DIN 02388804 · $0.3147
Losartan · DIN 02388871 · $0.3147
Mint-Losartan · DIN 02405741 · $0.3147
PMS-Losartan · DIN 02309769 · $0.3147
Ran-Losartan · DIN 02404478 · $0.3147
Septa-Losartan · DIN 02424975 · $0.3147
Teva-Losartan · DIN 02357968 · $0.3147
Shortage status: resolved shortage (ended 2024-11-18); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02313340
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Teva-Losartan · DIN 02357968 · 50mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Teva-Losartan · DIN 02357968
Manufacturer: Teva Canada Limited; listing date 2012-03-26
Health Canada: Marketed since 2012-01-25 · brand TEVA-LOSARTAN · ATC C09CA01 LOSARTAN · form Tablet · route Oral · ingredients LOSARTAN POTASSIUM 50 MG · company Teva canada limited · schedule Prescription
Ministry pays: $0.3147 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84304 · Verify on the e-Formulary ↗ (DIN 02357968)
Source record
DIN 02357968: Teva-Losartan
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800216; group id 335; item number 0758; lccId None; manufacturer id TEV
Source form: Tab; strength: 50mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.3148; ministry $0.3147
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02357968
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84304
Interchangeable products
Apo-Losartan · DIN 02353504 · $0.3147
Auro-Losartan · DIN 02403331 · $0.3147
Bio-Losartan · DIN 02445972 · $0.3147
Co Losartan · DIN 02354837 · $0.3147
Cozaar · DIN 02182874 · $0.3147
Jamp-Losartan · DIN 02398842 · $0.3147
Losartan · DIN 02388804 · $0.3147
Losartan · DIN 02388871 · $0.3147
Mint-Losartan · DIN 02405741 · $0.3147
PMS-Losartan · DIN 02309769 · $0.3147
Ran-Losartan · DIN 02404478 · $0.3147
Sandoz Losartan · DIN 02313340 · $0.3147
Septa-Losartan · DIN 02424975 · $0.3147
Shortage status: resolved shortage (ended 2024-03-28); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02357968
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Auro-Losartan · DIN 02403358 · 100mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Auro-Losartan · DIN 02403358
Manufacturer: Auro Pharma Inc.; listing date 2013-05-31
Health Canada: Marketed since 2013-03-26 · brand AURO-LOSARTAN · ATC C09CA01 LOSARTAN · form Tablet · route Oral · ingredients LOSARTAN POTASSIUM 100.0 MG · company Auro pharma inc · schedule Prescription
Auro-Losartan: Formulary list price $0.3147/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.3147 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88816 · Verify on the e-Formulary ↗ (DIN 02403358)
Source record
DIN 02403358: Auro-Losartan
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800230; group id 335; item number 0759; lccId None; manufacturer id AUR
Source form: Tab; strength: 100mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.3147; ministry $0.3147
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02403358
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88816
Interchangeable products
Apo-Losartan · DIN 02353512 · $0.3147
Bio-Losartan · DIN 02445980 · $0.3147
Co Losartan · DIN 02354845 · $0.3147
Cozaar · DIN 02182882 · $0.3147
Jamp-Losartan · DIN 02398850 · $0.3147
Losartan · DIN 02388812 · $0.3147
Losartan · DIN 02388898 · $0.3147
Mint-Losartan · DIN 02405768 · $0.3147
PMS-Losartan · DIN 02309777 · $0.3147
Ran-Losartan · DIN 02404486 · $0.3147
Sandoz Losartan · DIN 02313359 · $0.3147
Septa-Losartan · DIN 02424983 · $0.3147
Teva-Losartan · DIN 02357976 · $0.3147
Shortage status: resolved shortage (ended 2023-12-06); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02403358
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Cozaar · DIN 02182882 · 100mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Cozaar · DIN 02182882
Manufacturer: Organon Canada Inc.; listing date 1999-04-15
Health Canada: Marketed since 2022-01-07 · brand COZAAR · ATC C09CA01 LOSARTAN · form Tablet · route Oral · ingredients LOSARTAN POTASSIUM 100 MG · company Organon canada inc. · schedule Prescription
Ministry pays: $0.3147 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=44255 · Verify on the e-Formulary ↗ (DIN 02182882)
Source record
DIN 02182882: Cozaar
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800230; group id 335; item number 0759; lccId None; manufacturer id OCI
Source form: Tab; strength: 100mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $1.9924; ministry $0.3147
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02182882
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=44255
Interchangeable products
Apo-Losartan · DIN 02353512 · $0.3147
Auro-Losartan · DIN 02403358 · $0.3147
Bio-Losartan · DIN 02445980 · $0.3147
Co Losartan · DIN 02354845 · $0.3147
Jamp-Losartan · DIN 02398850 · $0.3147
Losartan · DIN 02388812 · $0.3147
Losartan · DIN 02388898 · $0.3147
Mint-Losartan · DIN 02405768 · $0.3147
PMS-Losartan · DIN 02309777 · $0.3147
Ran-Losartan · DIN 02404486 · $0.3147
Sandoz Losartan · DIN 02313359 · $0.3147
Septa-Losartan · DIN 02424983 · $0.3147
Teva-Losartan · DIN 02357976 · $0.3147
Shortage status: resolved shortage (ended 2022-01-07); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02182882
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Jamp-Losartan · DIN 02398850 · 100mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Jamp-Losartan · DIN 02398850
Manufacturer: Jamp Pharma Corporation; listing date 2013-05-31
Health Canada: Marketed since 2016-06-01 · brand JAMP-LOSARTAN · ATC C09CA01 LOSARTAN · form Tablet · route Oral · ingredients LOSARTAN POTASSIUM 100 MG · company Jamp pharma corporation · schedule Prescription
Jamp-Losartan: Formulary list price $0.3147/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.3147 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88377 · Verify on the e-Formulary ↗ (DIN 02398850)
Source record
DIN 02398850: Jamp-Losartan
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800230; group id 335; item number 0759; lccId None; manufacturer id JPC
Source form: Tab; strength: 100mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.3147; ministry $0.3147
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02398850
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88377
Interchangeable products
Apo-Losartan · DIN 02353512 · $0.3147
Auro-Losartan · DIN 02403358 · $0.3147
Bio-Losartan · DIN 02445980 · $0.3147
Co Losartan · DIN 02354845 · $0.3147
Cozaar · DIN 02182882 · $0.3147
Losartan · DIN 02388812 · $0.3147
Losartan · DIN 02388898 · $0.3147
Mint-Losartan · DIN 02405768 · $0.3147
PMS-Losartan · DIN 02309777 · $0.3147
Ran-Losartan · DIN 02404486 · $0.3147
Sandoz Losartan · DIN 02313359 · $0.3147
Septa-Losartan · DIN 02424983 · $0.3147
Teva-Losartan · DIN 02357976 · $0.3147
Shortage status: active shortage (reported 2026-02-26, estimated to end 2026-12-31, last updated 2026-03-28); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02398850
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Losartan · DIN 02388812 · 100mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Losartan · DIN 02388812
Manufacturer: Sivem Pharmaceuticals ULC; listing date 2020-06-30
Health Canada: Marketed since 2025-06-12 · brand LOSARTAN · ATC C09CA01 LOSARTAN · form Tablet · route Oral · ingredients LOSARTAN POTASSIUM 100 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Losartan: Formulary list price $0.3147/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.3147 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87433 · Verify on the e-Formulary ↗ (DIN 02388812)
Source record
DIN 02388812: Losartan
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800230; group id 335; item number 0759; lccId None; manufacturer id SIV
Source form: Tab; strength: 100mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.3147; ministry $0.3147
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02388812
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87433
Interchangeable products
Apo-Losartan · DIN 02353512 · $0.3147
Auro-Losartan · DIN 02403358 · $0.3147
Bio-Losartan · DIN 02445980 · $0.3147
Co Losartan · DIN 02354845 · $0.3147
Cozaar · DIN 02182882 · $0.3147
Jamp-Losartan · DIN 02398850 · $0.3147
Losartan · DIN 02388898 · $0.3147
Mint-Losartan · DIN 02405768 · $0.3147
PMS-Losartan · DIN 02309777 · $0.3147
Ran-Losartan · DIN 02404486 · $0.3147
Sandoz Losartan · DIN 02313359 · $0.3147
Septa-Losartan · DIN 02424983 · $0.3147
Teva-Losartan · DIN 02357976 · $0.3147
Shortage status: active shortage (reported 2021-05-26, last updated 2021-05-27) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02388812
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Losartan · DIN 02388898 · 100mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Losartan · DIN 02388898
Manufacturer: Sanis Health Inc.; listing date 2021-01-29
Health Canada: Marketed since 2012-07-20 · brand LOSARTAN · ATC C09CA01 LOSARTAN · form Tablet · route Oral · ingredients LOSARTAN POTASSIUM 100 MG · company Sanis health inc · schedule Prescription
Losartan: Formulary list price $0.3147/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.3147 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87443 · Verify on the e-Formulary ↗ (DIN 02388898)
Source record
DIN 02388898: Losartan
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800230; group id 335; item number 0759; lccId None; manufacturer id SAI
Source form: Tab; strength: 100mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.3147; ministry $0.3147
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02388898
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87443
Interchangeable products
Apo-Losartan · DIN 02353512 · $0.3147
Auro-Losartan · DIN 02403358 · $0.3147
Bio-Losartan · DIN 02445980 · $0.3147
Co Losartan · DIN 02354845 · $0.3147
Cozaar · DIN 02182882 · $0.3147
Jamp-Losartan · DIN 02398850 · $0.3147
Losartan · DIN 02388812 · $0.3147
Mint-Losartan · DIN 02405768 · $0.3147
PMS-Losartan · DIN 02309777 · $0.3147
Ran-Losartan · DIN 02404486 · $0.3147
Sandoz Losartan · DIN 02313359 · $0.3147
Septa-Losartan · DIN 02424983 · $0.3147
Teva-Losartan · DIN 02357976 · $0.3147
Shortage status: resolved shortage (ended 2025-10-08); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02388898
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Mint-Losartan · DIN 02405768 · 100mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Mint-Losartan · DIN 02405768
Manufacturer: Mint Pharmaceuticals Inc.; listing date 2014-05-29
Health Canada: Marketed since 2024-03-22 · brand MINT-LOSARTAN · ATC C09CA01 LOSARTAN · form Tablet · route Oral · ingredients LOSARTAN POTASSIUM 100 MG · company Mint pharmaceuticals inc · schedule Prescription
Mint-Losartan: Formulary list price $0.3147/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.3147 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89052 · Verify on the e-Formulary ↗ (DIN 02405768)
Source record
DIN 02405768: Mint-Losartan
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800230; group id 335; item number 0759; lccId None; manufacturer id MIN
Source form: Tab; strength: 100mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.3147; ministry $0.3147
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02405768
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89052
Interchangeable products
Apo-Losartan · DIN 02353512 · $0.3147
Auro-Losartan · DIN 02403358 · $0.3147
Bio-Losartan · DIN 02445980 · $0.3147
Co Losartan · DIN 02354845 · $0.3147
Cozaar · DIN 02182882 · $0.3147
Jamp-Losartan · DIN 02398850 · $0.3147
Losartan · DIN 02388812 · $0.3147
Losartan · DIN 02388898 · $0.3147
PMS-Losartan · DIN 02309777 · $0.3147
Ran-Losartan · DIN 02404486 · $0.3147
Sandoz Losartan · DIN 02313359 · $0.3147
Septa-Losartan · DIN 02424983 · $0.3147
Teva-Losartan · DIN 02357976 · $0.3147
Shortage status: resolved shortage (ended 2024-03-22); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02405768
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (24:08 Hypotensive Drugs (For Diuretics See 40:28)) and how they are covered
Matched class: 24:08 Hypotensive Drugs (For Diuretics See 40:28)
Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment.
Covered without a code on the Ontario formulary: CANDESARTAN CILEXETIL, CANDESARTAN CILEXETIL & HYDROCHLOROTHIAZIDE, CILAZAPRIL & HYDROCHLOROTHIAZIDE, LABETALOL HCL, MINOXIDIL, OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL & HYDROCHLOROTHIAZIDE, PERINDOPRIL ERBUMINE, PERINDOPRIL ERBUMINE & INDAPAMIDE, PINDOLOL & HYDROCHLOROTHIAZIDE, TELMISARTAN, TELMISARTAN & AMLODIPINE BESYLATE, TELMISARTAN & HYDROCHLOROTHIAZIDE, VALSARTAN & HYDROCHLOROTHIAZIDE
Some products covered without a code (check the product listing): ATENOLOL & CHLORTHALIDONE, BENAZEPRIL, CAPTOPRIL, CILAZAPRIL, CLONIDINE HCL, DOXAZOSIN MESYLATE, ENALAPRIL MALEATE, FELODIPINE, FOSINOPRIL SODIUM, HYDRALAZINE HCL, IRBESARTAN, IRBESARTAN & HYDROCHLOROTHIAZIDE, LISINOPRIL, LISINOPRIL & HYDROCHLOROTHIAZIDE, METHYLDOPA, NIFEDIPINE, PINDOLOL, PRAZOSIN HCL, QUINAPRIL, QUINAPRIL & HYDROCHLOROTHIAZIDE, RAMIPRIL, RAMIPRIL & HYDROCHLOROTHIAZIDE, TERAZOSIN HCL, TRANDOLAPRIL, VALSARTAN, VERAPAMIL HCL
24:08 Hypotensive Drugs (For Diuretics See 40:28)
· 59 products · General benefit · strengths: 4mg, 8mg, 16mg, 32mg · Tab
· 41 products · Listed, not a benefit (1), General benefit (40) · strengths: 75mg, 150mg, 300mg · Tab
· 22 products · General benefit · strengths: 20mg, 40mg · Tab
· 25 products · General benefit · strengths: 40mg, 80mg · Tab
· 38 products · Off-Formulary Interchangeable, not an ODB benefit (10), General benefit (28) · strengths: 40mg, 80mg, 160mg, 320mg · Tab
· 2 products · General benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada · strengths: 400mg, 600mg · Tab
· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 50 & 25mg, 100 & 25mg · Tab
· 6 products · Listed, not a benefit (3), General benefit (3) · strengths: 5mg, 10mg, 20mg · Tab
· 21 products · General benefit · strengths: 16mg & 12.5mg, 32mg & 12.5mg, 32mg & 25mg · Tab
· 14 products ·
Limited Use, codes 707, 723 (2), Listed, not a benefit (4), General benefit (8) · strengths: 5mg/5mL, 25mg/5mL, 12.5mg, 25mg, 50mg, 100mg · Oral Sol, Tab
· 8 products · Listed, not a benefit (2), General benefit (6) · strengths: 1mg, 2.5mg, 5mg · Tab
· 2 products · General benefit · strengths: 5mg/12.5mg · Tab
Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 24:08
and 34 more